Stockscreener 앱 받기
29.97
2.42%
-0.63
Biodesix Inc 주식(BDSX)의 최신 뉴스
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - Vinanet
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com
Biodesix at Canaccord Genuity conference: growth, margins in focus By Investing.com - Investing.com Nigeria
Biodesix (BDSX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Biodesix (BDSX) major holder Jack W. Schuler adds shares via trusts - Stock Titan
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference - TradingView
Biodesix 10% owner Jack W. Schuler reports $669,537 common share purchase - Bitget
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Canaccord raises Biodesix stock price target on strong test volume By Investing.com - Investing.com India
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet - Yahoo Finance
BDSX Maintained by Canaccord Genuity -- Price Target Raised to $35 - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Canaccord raises Biodesix stock price target on strong test volume - Investing.com India
HC Wainwright Forecasts Biodesix's Q3 Earnings (NASDAQ:BDSX) - MarketBeat
Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67 - webull.com
H.C. Wainwright Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Biodesix Inc (BDSX) Stock News Today - TradingKey
Biodesix boosts sales, trims loss as diagnostics firm pushes toward profitability - BizWest
A Quick Look at Today's Ratings for Biodesix(BDSX.US), With a Forecast Between $27 to $40 - Moomoo
Biodesix (BDSX) Stock Pullback Puts Focus On Losses Despite Stronger Margins - Sahm
BDSX Maintains Buy Rating -- Price Target Raised to $27.00 by HC Wainwright - GuruFocus
Biodesix, Inc. Stock 12‑Month Price Target Raised to $32.67, Implies 43% Upside - TradingView
Biodesix, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
William Blair Initiates Biodesix(BDSX.US) With Buy Rating - Moomoo
CCORF Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Earnings call transcript: Biodesix tops revenue forecast in Q2 2026, shares fall after hours - Investing.com Nigeria
Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic Testing Growth - GuruFocus
Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic ... - Yahoo Finance
Is Biodesix Inc (BDSX) Overvalued After Q2 2026 Earnings Beat? G - GuruFocus
Biodesix Q2 Earnings Call Highlights - MarketBeat
Biodesix (NASDAQ:BDSX) Announces Earnings Results - MarketBeat
Biodesix Q2 2026 earnings: Diagnostic testing growth narrows losses - TradingKey
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Biodesix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Biodesix (NASDAQ:BDSX) Q2 EPS Beats, Revenue In Line, Shares Slip - ChartMill
BIODESIX ($BDSX) Releases Q2 2026 Earnings - Moomoo
Biodesix Q2 revenue rises 34%, beats analyst estimates - TradingView
Biodesix Posts Q2 2026 Revenue $26.9M; Gross Margin 82%, Adjusted EBITDA Loss Narrows - TradingView
BIODESIX Inc Q2 2026: Revenue $26.86M, EPS $(0.71) — 10-Q Summary - TradingView
Biodesix Announces Second Quarter 2026 Results and Highlights - The Manila Times
Biodesix (NASDAQ: BDSX) lifts lung test revenue and raises $23.9M equity - Stock Titan
Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
0.91%
0.52%
자본화:
|
볼륨(24시간):